

---

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**

Washington, D. C. 20549

---

**FORM 8-K**

**CURRENT REPORT  
Pursuant to Section 13 or 15(d) of the  
Securities Exchange Act of 1934**

**October 21, 2016**

Date of Report (Date of earliest event reported)

**ABBOTT LABORATORIES**

(Exact name of registrant as specified in charter)

---

**Illinois**

(State or other Jurisdiction of Incorporation)

**1-2189**

(Commission File Number)

**36-0698440**

(IRS Employer Identification No.)

---

**100 Abbott Park Road**

**Abbott Park, Illinois 60064-6400**

(Address of principal executive offices)(Zip Code)

Registrant's telephone number, including area code: **(224) 667-6100**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  - ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  - ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
- 
- 

**Item 8.01 Other Events.**

On October 21, 2016, Abbott Laboratories ("Abbott") completed the cancellation of its listing of Abbott common shares on the London Stock Exchange. Abbott's common shares continue to be listed on the New York Stock Exchange, the Chicago Stock Exchange and the SIX Swiss Exchange.

2

---

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**ABBOTT LABORATORIES**

Date: October 24, 2016

By: /s/ Brian B. Yoor  
Brian B. Yoor  
Senior Vice President, Finance and Chief  
Financial Officer

3

